Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells

Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and wh-4 on the proliferation...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Su-Hong, Xu, Dan-Dan, Zhou, Peng-Jun, Wang, Yao, Liu, Qiu-Ying, Ren, Zhe, Liu, Zhong, Wang, Xia, Huang, Hui-Qing, Xue, Xue, Wang, Ying, Wang, Yi-Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815050/
https://www.ncbi.nlm.nih.gov/pubmed/35222709
http://dx.doi.org/10.3892/etm.2022.11156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815050/
https://www.ncbi.nlm.nih.gov/pubmed/35222709
http://dx.doi.org/10.3892/etm.2022.11156

Ejemplares similares